The Promise of Artificial Intelligence-Aided Pathology in Thoracic Oncology

Challenges of Systemic Therapy for Patients with EGFR-mutated Lung Cancer After Progression on Targeted Therapy

No PFS, OS Benefit Seen in Final Results from PACIFIC-2

MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination

Can Artificial Intelligence Identify Those at High Risk and Shift the Lung Cancer Screening Paradigm?

Mounting Evidence Supporting Neoadjuvant ChemoIO Means Surgeons Must Adapt

More Than Ever, Surgeons Must Collaborate to Ensure Patients Receive Appropriate Care

A New Treatment Option for Early-Stage ALK+ NSCLC: Adjuvant Alectinib

Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2

Transporting Real-World Evidence Between Countries—Ready to Beam Aboard?

Proposed Criteria for Tumor Invasion Align with Clinical Factors, Offer Better Predictability, Study Finds

Modified Lung Cancer Screening Eligibility Requirements May Reduce Racial Disparities in Lung Cancer Screening, Treatment